Literature DB >> 20022872

Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: Impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation.

Stefan Grajek1, Małgorzata Popiel, Lidia Gil, Piotr Breborowicz, Maciej Lesiak, Rafał Czepczyński, Krzysztof Sawiński, Ewa Straburzyńska-Migaj, Aleksander Araszkiewicz, Anna Czyz, Maria Kozłowska-Skrzypczak, Mieczysław Komarnicki.   

Abstract

AIMS: Randomized trial to assess change in left ventricle ejection fraction (LVEF) and myocardial perfusion in patients with acute myocardial infarction (AMI) of anterior wall treated with bone marrow stem cells (BMSCs), compared with control group-from baseline in the acute phase up to 12 months of follow-up. METHODS AND
RESULTS: Forty-five patients were randomized 2:1 to BMSC group (n= 31) or to control group (n = 14). Bone marrow stem cells were administered into infarct-related artery (IRA) at 4-6 day after primary PCI. Groups were followed up with Tc-99m-MIBI SPECT, radionuclide ventriculography (EF-RNV), echocardiography (ECHO), and spiroergometric stress test. Coronary angiography was repeated after 6 months. EF-RNV did not differ significantly in both groups, but trend towards increase in EF at 6 months and its maintenance after 12 months was noticed in the BMSC group. At rest study, perfusion index (PI) of region supplied with blood by IRA distal to its previous occlusion (PI-IRA) improved significantly in the BMSC group at 6 months: PI-IRA at 4-6 days vs. PI-IRA at 6 months (3.00 +/- 0.97 vs. 2.65 +/- 0.64; P = 0.017). At 12 months, PI-IRA at rest was 2.66 +/- 0.55; P = 0.07. The difference between BMSC and control groups at rest study in PI-IRA was not observed. At dipyridamole study (PI-dip), perfusion in the BMSC group was better compared with controls at 6 months (2.26 +/- 0.44 vs. 2.47 +/- 0.40; P = 0.033) and at 12 months (2.34 +/- 0.55 vs. 2.52 +/- 0.42; P = 0.014), also for region supplied with blood by IRA (PI-IRA-dip; at 6 months 2.63 +/- 0.77 vs. 3.06 +/- 0.46; P = 0.021 and at 12 months 2.71 +/- 0.63 vs. 3.15 +/- 0.51; P = 0.001). Results of LVEF, LVEDV, LVESV in ECHO and results of spiroergometric stress test did not differ significantly between groups. Major adverse cardiac events occurred more often in the control group (P = 0.027).
CONCLUSION: In our study, BMSC intracoronary transplantation in patients with anterior AMI did not result in increase in EF. Slight improvement of myocardial perfusion was noticed in the BMSC group. This finding may indicate better microcirculation enhanced by BMSCs, but small number of patients allow for hypothesis rather than final statement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022872     DOI: 10.1093/eurheartj/ehp536

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  37 in total

Review 1.  SPECT and PET to optimize cardiac stem cell therapy.

Authors:  Angel T Chan; M Roselle Abraham
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

Review 2.  Cell delivery routes for stem cell therapy to the heart: current and future approaches.

Authors:  Niall G Campbell; Ken Suzuki
Journal:  J Cardiovasc Transl Res       Date:  2012-05-31       Impact factor: 4.132

3.  The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion.

Authors:  Kamel Sadat; Sameer Ather; Wael Aljaroudi; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2013-12-31       Impact factor: 5.952

4.  Improved targeting and enhanced retention of the human, autologous, fibroblast-derived, induced, pluripotent stem cells to the sarcomeres of the infarcted myocardium with the aid of the bioengineered, heterospecific, tetravalent antibodies.

Authors:  Marek Malecki
Journal:  J Stem Cell Res Ther       Date:  2013-05-06

Review 5.  Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis.

Authors:  Ronak Delewi; Alexander Hirsch; Jan G Tijssen; Volker Schächinger; Wojciech Wojakowski; Jérôme Roncalli; Svend Aakhus; Sandra Erbs; Birgit Assmus; Michal Tendera; R Goekmen Turan; Roberto Corti; Tim Henry; Patricia Lemarchand; Ketil Lunde; Feng Cao; Heikki V Huikuri; Daniel Sürder; Robert D Simari; Stefan Janssens; Kai C Wollert; Michal Plewka; Stefan Grajek; Jay H Traverse; Felix Zijlstra; Jan J Piek
Journal:  Eur Heart J       Date:  2013-09-11       Impact factor: 29.983

6.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

Review 7.  Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Authors:  Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circulation       Date:  2012-06-22       Impact factor: 29.690

Review 8.  Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: Repair and regeneration.

Authors:  Rogelio Zamilpa; Mary M Navarro; Iris Flores; Sy Griffey
Journal:  World J Cardiol       Date:  2014-07-26

Review 9.  "Second-generation" stem cells for cardiac repair.

Authors:  Alberto Núñez García; Ricardo Sanz-Ruiz; María Eugenia Fernández Santos; Francisco Fernández-Avilés
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

10.  Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device.

Authors:  Deepak K Gupta; Hicham Skali; Jose Rivero; Patricia Campbell; Leslie Griffin; Colleen Smith; Courtney Foster; Brian Claggett; Robert J Glynn; Gregory Couper; Michael M Givertz; Mandeep R Mehra; Marcelo Di Carli; Scott D Solomon; Marc A Pfeffer
Journal:  J Heart Lung Transplant       Date:  2014-01-27       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.